Janssen withdraws from Horizon Therapeutics bidding war without making offer
The pharmaceutical arm of Johnson & Johnson has bowed out of the race to acquire Horizon Therapeutics, which sells Genmab’s best-selling eye treatment Tepezza.
by ulrich quistgaard, translated by catherine brett
Until now, there were three contenders for the acquisition of Horizon Therapeutics.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Horizon confirms buyer interest from Amgen, Janssen, Sanofi
For subscribers
Genmab cancer drug incomes surpass USD 400m in Q3
For subscribers
Analyst spots strong figures behind Genmab upgrade
For subscribers
